As concerns mount about the impact the ongoing coronavirus outbreak is having on active pharmaceutical ingredient (API) manufacturing in China, some of the most pressing questions on Mylan NV’s fourth quarter and full year 2019 earnings report on 27 February were not about the company’s pending debut as Viatris GMBH or on its recent performance – but on how the global generics giant expected the situation to affect drug supply.
Opening the call, CEO Heather Bresch commented that although Mylan’s business exposure in China is limited, “given the global nature...








